NLNorman López

Norman López

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Norman López has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Breiner Morales-Asencio

    Consorcio Latinoamericano de Investigación (Clati)

    5 shared publications
  • Cesar Castellanos

    11 Instituto Dominicano para el Estudio de la Salud Integral y la Psicología Aplicada (IDESIP), Santo Domingo, Dominican Republic

    5 shared publications
  • Juan-Carlos Coronado

    Departamento de Procesos Terapéuticos, Facultad de Ciencias de la Salud, Universidad Católica de Temuco

    5 shared publications
  • César Quispe-Ayala

    Universidad Nacional de Huancavelica, Huancavelica, Peru

    4 shared publications
  • Daniela Ripoll-Córdoba

    Consorcio Latinoamericano de Investigación (CLATI), Temuco, Chile

    4 shared publications
  • Nicole Caldichoury

    Departamento de Ciencias Sociales, Universidad de Los Lagos, Osorno, Chile

    4 shared publications

Latest Publications

  • Open Access

    Long-term outcomes after caudal zona incerta-forel field ablation: three-year clinical follow-up in advanced Parkinson’s disease

    by Boris Zurita-Cueva, Luis Vaca-Burbano, Cleto Ramírez-Penso, Mauricio Navarrete-Carreño, Andris Mejía, Juan-Carlos Coronado, Breiner Morales-Asencio, Carol Saldías, Norman López

    Introduction: Advanced Parkinson’s disease (PD) with a tremor–rigid phenotype poses therapeutic challenges when pharmacological treatments lose efficacy and deep brain stimulation (DBS) is not an option; particularly in contexts where access to implantable neuromodulation therapies is limited. In this scenario, stereotactic ablation of the caudal zona incerta (cZI) and the Fields of Forel has emerged as a surgical alternative, although long-term evidence remains scarce, especially for combined infrathalamic approaches. Methods: A prospective study was conducted in 10 patients with advanced unilateral PD and a tremor-rigid phenotype, treated with stereotactic radiofrequency in the cZI and Fields of Forel. Motor function was assessed using the UPDRS III at six time points (baseline, 3, 6, 12, 24, and 36 months), allowing the analysis of both early response and long-term clinical stability. Paired Student’s t -tests were applied to compare longitudinal changes in UPDRS III between baseline and follow-up assessments. In addition, effect sizes were calculated using Cohen’s d. Results: UPDRS III scores were significantly reduced at all follow-ups ( p < 0.001), with mean decreases of −25.8 points at 3 months and −36.3 points at 36 months. Effect sizes were very large (d > 4.0). Tremor improved early and was sustained; rigidity and bradykinesia showed marked reductions during the first year with a slight subsequent upward trend; gait demonstrated continuous progression up to 36 months. No major complications were recorded, and transient adverse effects were minimal, consisting of mild and transient postoperative imbalance in two patients, with rapid clinical recovery and no permanent sequelae. Conclusion: Stereotactic ablation of the cZI and Fields of Forel provides robust and sustained clinical benefits at 3 years, with a favourable safety profile. These findings highlight the durability of the motor effect of infrathalamic ablative approaches and position this technique as a viable alternative to DBS in selected patients with advanced PD; underscoring the need for multicentre studies to consolidate its role in contemporary functional surgery.


  • Open Access

    Reliability and convergent validity of the PHQ-2 for the rapid detection of depressive symptoms in healthcare professionals in Argentina

    by Nicole Caldichoury, Breiner Morales-Asencio, Juan-Carlos Coronado, Luis Mario Castellanos-Alvarenga, César Quispe-Ayala, Carol Saldías, David Salazar, Daniela Ripoll-Córdoba, Wendy Bada, Juan Martínez, et al.

    Introduction: The prevalence of depressive symptoms among healthcare professionals has increased significantly, highlighting the need for valid and reliable ultra-rapid screening tools in high-demand clinical settings. Objective: To analyze the reliability and convergent validity of the Patient Health Questionnaire-2 (PHQ-2) among healthcare professionals in Argentina. Method: A cross-sectional eHealth study was conducted with 2,835 healthcare professionals (47% men, 53% women) working in public (57.2%) and private (42.8%) institutions. Participants completed the PHQ-2, PHQ-9, GAD-7, and Mini-Z scales in two phases, with a three-month interval. The convergent validity of the test was determined by comparing it with the original version of the PHQ, an anxiety test (GAD-7), and a burnout test (Mini-Z). In addition, internal consistency was calculated using Cronbach's alpha coefficient and McDonald's omega coefficient. Results: The PHQ-2 showed a unidimensional structure, explaining 73% of the variance, and demonstrated strong convergent validity, with high correlations with the PHQ-9 (r = 0.836; p < 0.001) and the GAD-7 (r = 0.724; p < 0.001), and a moderate correlation with the Mini-Z (r = 0.568; p < 0.001). Internal consistency was satisfactory (α = 0.75; ω = 0.85), confirming its reliability as a screening tool. Conclusions: The PHQ-2 is a valid and reliable instrument for the ultra-rapid detection of depressive symptoms in healthcare professionals in Argentina. Its strong psychometric properties and brief format make it a useful tool for mental health screening in high-demand healthcare settings.

  • Open Access

    Factorial invariance of the Spanish version of the PHQ-9 by gender and country in Latin America and the Caribbean

    by Nicole Caldichoury, Breiner Morales-Asencio, Luis Mario Castellanos-Alvarenga, Juan-Carlos Coronado, César Quispe-Ayala, Daniela Ripoll-Córdoba, Carol Saldías, Wendy Bada, Karen Alcos-Flores, Boris Zurita-Cueva, et al.

    Introduction: Depression is one of the leading causes of global disease burden, particularly in regions with high inequality such as Latin America and the Caribbean (LAC). The Patient Health Questionnaire-9 (PHQ-9) is one of the most widely used instruments internationally for screening depressive symptoms, although its structural validity and diagnostic comparability in LAC still require further evidence. Objective: To examine the factorial structure, invariance by sex and country, internal consistency, and concurrent validity of the PHQ-9 in a multinational sample of Latin American adults. Method: Data from 12,124 participants across 15 LAC countries were analyzed, collected through an online form using snowball sampling. Confirmatory factor analysis (CFA) and multigroup invariance analysis were applied, along with Omega coefficient and correlations with GAD-7 and Mini-Z. Results: The PHQ-9 showed a unidimensional structure with excellent fit (CFI = .989; RMSEA = .075), adequate internal consistency (Ω = .89), and evidence of configural, metric, scalar, and strict invariance by sex and country. High correlation with GAD-7 (r = .79) and moderate correlation with Mini-Z (r = .64) supported its concurrent validity. Conclusion: The PHQ-9 demonstrated robust psychometric properties and diagnostic comparability across countries and sexes in LAC. These findings reinforce its utility as a standardized and culturally adaptable tool for screening depressive symptoms in clinical and community settings in the region.

  • Open Access

    Clinical utility of the GAD-7 for detecting generalized anxiety in Quechua indigenous people

    by Nicole Caldichoury, César Quispe-Ayala, Juan-Carlos Coronado, Luis Castellanos-Alvarenga, David Salazar, Breiner Morales-Asencio, Daniela Ripoll-Córdoba, Raúl Quincho-Apumayta, Juan Cárdenas-Valverde, Loida Camargo, et al.

    The detection of Generalized Anxiety Disorder (GAD) in indigenous populations poses a challenge due to their holistic approach to health, which significantly contrasts with the Western biomedical model. Moreover, conventional assessment tools often overlook cultural particularities, compromising their effectiveness in these contexts.Objective: Therefore, this study aimed to analyze the diagnostic accuracy of the GAD-7 in the Quechua indigenous population of the Peruvian Andes.Method: To address this issue, we conducted a case-control study to evaluate the clinical accuracy of the Generalized Anxiety Disorder Test (GAD-7) in rural Quechua communities of the Peruvian Andes. We included 147 GAD patients and 322 controls. The study involved four stages: cultural adaptation of the GAD-7, door-to-door evaluation, blind psychiatric and neuropsychological assessments, and application of the Quechua GAD-7. The adaptation used the Delphi method, focus groups, and bilingual judges. Factor analyses, reliability assessments, and diagnostic utility evaluations were performed.Results: The Quechua GAD-7 showed high content validity (Aiken’s V > 0.85), strong internal consistency (α = 0.912, ω = 0.85), and an area under the curve of 0.93. With a cutoff score of 11, it achieved 91.3% sensitivity and 86.1% specificity.Conclusions: This is the first study to validate a Western test for GAD in indigenous populations.


  • Neurocognitive Effects of Substance Abuse and Their Measurement with Neuropsychological Tests

    by Norman López, Jorge Herrera, Yuliana Flórez, Cesar Castellanos, Pascual Ángel Gargiulo


  • Educational Procedures for Patients with Alcohol Addiction: Considerations from Medicine and Nursing

    by Virginia Leonor Herbas Pacheco, Pascual Jiménez Aguilar, Ana María Arias, Ruth Ávila Herbas, Virginia Ramos Chuquimia, Yuliana Flórez, Norman Darío López Velásquez, Augusto Pascual Ítalo Gargiulo, Luis Echarte Alonso, Pascual Ángel Gargiulo

  • Neuropsychological Instruments for the Evaluation of Alcohol Abuse Disorders

    by Jorge Herrera, Norman López, Carol Saldías Solís, Daniela Ripoll, Andrés Ledezma, Yuliana Flórez, Breiner Morales, Pascual Ángel Gargiulo


  • Clinical validation of the GAD-7 for the Peruvian Quechua population

    by Norman López, Juan-Carlos Coronado, César Quispe-Ayala, Paola García-Roncallo, Juan Cárdenas-Valverde, Yuliana Flórez, Régulo Antezana, David Salazar, Raúl Quincho-Apumayta, Carol Saldías, et al.


  • Open Access

    Effectiveness of deep brain stimulation on refractory aggression in pediatric patients with autism and severe intellectual disability: meta-analytic review

    by Jorge Herrera-Pino, Juancarlos Benedetti-Isaac, Daniela Ripoll-Córdoba, Loida Camargo, Edgard E. Castillo-Tamara, Breiner Morales-Asencio, Esther Perea-Castro, Martín Torres Zambrano, Alejandro Ducassou, Yuliana Flórez, et al.

    Some patients with autism and severe intellectual disability may experience uncontrolled aggression, causing serious injury or harm to others, and the therapeutic ineffectiveness of traditional pharmacological and behavioral treatment may aggravate symptoms. Deep brain stimulation (DBS) has been tested in patients with little evidence in children and adolescents. Therefore, we analyzed the efficacy and safety of DBS in refractory aggression in pediatric subjects with autism (ASD) and severe intelligence deficit (ID).Methods A meta-analytic review of Web of Science (WOS) and Scopus articles, following Prisma criteria. A total of 555 articles were identified, but after applying the inclusion criteria, only 18 were analyzed. The review of the registries and the extraction of information was performed by 2 independent groups, to reduce the evaluator’s bias. For the description of the results, pediatric patients with ASD or ID present in each registry, with an application of specialized scales (Overt aggression scale, OAS, and THE modified version of the OAS, MOAS) pre and post-DBS, with a clinical follow-up of at least 12 months, were considered valid. Clinical improvement was calculated using tests of aggressiveness. In each registry with available data and then pooling the means of all patients in the OAS and MOAS, the effect size of DBS (overall and per study) was estimated. Finally, the adapted NOS scale was applied to rate the studies’ quality and level of bias.Results In the studies analyzed, 65/100 were pediatric patients, with a mean age of 16.8 years. Most of the studies were conducted in South America and Europe. In all teams, aggressive behavior was intractable, but only 9 groups (53/65) applied specialized scales to measure aggressiveness, and of these, only 51 subjects had a follow-up of at least 12 months. Thus, in 48/51 a clinical improvement of patients was estimated (94.2%), with a considerable overall effect size (OAS: d = 4.32; MOAS: d = 1.46). However, adverse effects and complications were found in 13/65 subjects undergoing DBS. The brain target with the most evidence and the fewest side effects was the posteromedial hypothalamic nuclei (pHypN). Finally, applying the adapted NOS scale, quality, and bias, only 9 studies show the best indicators.Conclusion An optimal level of efficacy was found in only half of the publications. This is mainly due to design errors and irrelevant information in the reports. We believe that DBS in intractable aggressiveness in children and adolescents with ASD and severe ID can be safe and effective if working groups apply rigorous criteria for patient selection, interdisciplinary assessments, objective scales for aggressiveness, and known surgical targets.